ECOG-ACRIN EAY131-Z1C

Primary Category:

Treatment Protocols

Disease Category:

Molecular Profiling

Status:

Temporarily Closed

MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC

(See required screening study ECOG-ACRIN EAY131)

EAY131 (MATCH) Subprotocol Z1C is suspended effective 10/18/18.

EAY131 (MATCH) Subprotocol Z1C  is nearing the completion of its accrual goal, and only a limited number of available treatment assignment slots remain. 09/21/18

Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol for a list of the designated laboratories and applicable subprotocols.

The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study.  Please contact Amber Boerner, aboerner@mtcancer.org or 406-969-6067, for the consent & for any questions.

NCT#02465060